[Bio USA] Lotte Biologics Accelerates CDMO Business with Successive Production Contracts

Establishment of 1,000-Liter Purification Facility and Advanced ADC Production Infrastructure
New York Syracuse Plant as "Global Hub," Incheon Songdo as "Mass Production Base"

Lotte Biologics has completed the expansion of its antibody-drug conjugate (ADC) production facility and signed its first production contract, accelerating its contract development and manufacturing organization (CDMO) business.

James Park, CEO of Lotte Biologics, held a press conference on June 18 (local time) at the 2025 BIO International Convention (Bio USA) in Boston, USA. He stated, "On the technology side, we are strengthening next-generation technologies such as ADC, and on the infrastructure side, we will provide customized services through our Syracuse and Songdo plant network." He added, "We aim to establish ourselves as a CDMO that grows together with customers in the rapidly changing bio industry."

Lotte Biologics recently invested about $100 million (approximately 140 billion KRW) in the Syracuse Bio Campus in New York, USA, to establish purification facilities with a maximum capacity of 1,000 liters and advanced ADC production infrastructure.

CEO Park said, "The newly expanded ADC production facility is an advanced manufacturing plant that integrates various elements, including state-of-the-art safety design, cross-contamination prevention, high-efficiency production lines, and strict quality control." He added, "We have acquired the capability to proactively respond to the production demand for next-generation biopharmaceuticals."

The company is also accelerating its efforts to differentiate its technology, centering on its proprietary ADC platform, 'Soluflex Link.' Soluflex Link is a technology that increases the solubility of linker-payloads and enhances the hydrophilicity of ADCs, thereby maximizing the stability and efficacy of the drugs. It can flexibly respond to a wide range of indications.

Based on these achievements, Lotte Biologics signed a contract in April with an Asia-based biotech company for the production of ADC clinical candidate substances. CEO Park introduced, "We are providing solutions that help our clients save time and costs through one-stop services that cover the entire process from clinical development to commercial production."

The company also announced plans to utilize the New York Syracuse Bio Campus as a "global hub" and the Incheon Songdo Bio Campus as a "mass production base." Lotte Biologics is currently preparing to operate its Incheon Songdo Bio Campus plant, which is capable of large-scale commercial production. The goal is to begin operating the first plant by 2027 to meet global mass production demand. While the Syracuse Bio Campus in North America will serve as a "one-stop CDMO hub from antibodies to ADCs," Songdo will play a complementary role as a "mass production base."

The company also expressed high expectations regarding the antibody drug contract manufacturing agreement signed the previous day with biotech company Otimopharma. Park said, "I cannot share specific details, but it is one of the targets that global big pharma companies are eyeing." He added, "We aim to complete the project within 12 months and prepare a white paper afterward." Oh Hanna, Head of Business Development at Lotte Biologics, added, "Although it is currently at the Phase 1 clinical trial stage, if the results are favorable, it has the potential to become a global blockbuster."

Meanwhile, Shin Yoo-yeol, Executive Vice President of Lotte Holdings and Head of Global Strategy at Lotte Biologics, who is the eldest son of Lotte Group Chairman Shin Dong-bin, also attended Bio USA to strengthen networks with global companies and directly monitor industry trends.